Regulatory Applications and Launch of New Generic Drug Products
First written in FY2016. 6 of 9 entries say "Advanced", first in FY2017. Latest entry: 2026-08-17.
3 other companies' latest entry also says "Advanced".
- FY2025-H1AdvancedAnnual report
「The Company began selling active pharmaceutical ingredients for formulations listed in the NHI drug price standard in December 2024, and sales of active pharmaceutical ingredients for generic products, including blood coagulation inhibitors, diabetes treatments and antipyretic analgesic anti-inflammatory drugs, remained firm.」
The disclosure states that sales of active pharmaceutical ingredients for formulations listed in the NHI drug price standard in December 2024 have begun, indicating progress into the post-development and post-launch sales phase. - FY2018Development pipeline updatedAnnual report
「During the consolidated fiscal year, the Company filed marketing authorization applications for 3 new supplemental generic products in 4 strengths and established their formulation designs and commercial manufacturing processes. It is currently proceeding with formulation design for 6 products in 13 strengths with a view to launching them.」
The number of applications for new supplemental products and the number of products and strengths targeted for launch have been updated. Although the numerical breakdown has changed from the previous fiscal year's disclosure, no change in direction has been explicitly stated. - FY2017AdvancedAnnual report
「The Company has filed marketing authorization applications for 3 new supplemental products in 5 strengths and has established their formulation designs and commercial manufacturing processes. Separately, it is proceeding with formulation design for 7 products in 12 strengths with a view to launching them.」
The development status toward applications and launches of products and strengths has been updated from the previous fiscal year's disclosure, which also now reports the establishment of commercial manufacturing processes. - FY2016First statedAnnual report
「The Company has filed marketing authorization applications for a total of 5 new supplemental products, comprising 1 product for rheumatoid arthritis, 1 allergy product (2 strengths of standard tablets, 1 strength of chewable tablets and 1 strength of fine granules), 1 hyperlipidemia product (3 strengths of orally disintegrating tablets) and 2 antihypertensive products (7 strengths), for a total of 14 strengths.」
Separately, the Company is proceeding with formulation design for 4 products in 5 strengths with a view to launching them.